# A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

> **NCT06445400** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 83 (actual)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** BL-M07D1
- **DRUG:** Pertuzumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT06445400
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-19
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2026-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06445400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06445400, "A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT06445400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*